BCMU
ALXN

BlueCrest Capital Management (UK)’s Alexion Pharmaceuticals ALXN Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,564
Closed -$244K – 730
2014
Q2 		$244K Buy
+1,564
New +$247K 0.01% 529

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlueCrest Capital Management (UK)'s ALXN Position: Q3 2014 in Review

BlueCrest Capital Management (UK) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2014, closing a stake of 1,564 shares — an estimated $244K sold.

BlueCrest Capital Management (UK) first reported a position in ALXN in Q2 2014 and held it in 1 quarter. The position peaked at $244K in Q2 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • BlueCrest Capital Management (UK) reported no remaining Alexion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 1,564 Alexion Pharmaceuticals shares in Q3 2014, an estimated $244K.
  • BlueCrest Capital Management (UK) first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Alexion Pharmaceuticals position peaked at $244K in Q2 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.